Kintara Therapeutics Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kintara Therapeutics stock.
View analyst ratings for Kintara Therapeutics or view top-rated stocks.

Wall Street analysts have given Kintara Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kintara Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Kintara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, September 20th 2021.
View our earnings forecast for Kintara Therapeutics.

Kintara Therapeutics, Inc. (NASDAQ:KTRA) issued its earnings results on Friday, May, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.05.
View Kintara Therapeutics' earnings history.

Kintara Therapeutics' stock was trading at $0.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KTRA stock has increased by 153.8% and is now trading at $1.32.
View which stocks have been most impacted by COVID-19.

Shares of Kintara Therapeutics reverse split on the morning of Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 7th 2019. An investor that had 100 shares of Kintara Therapeutics stock prior to the reverse split would have 10 shares after the split.

2 brokers have issued 12-month price targets for Kintara Therapeutics' shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate Kintara Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 278.8% from the stock's current price.
View analysts' price targets for Kintara Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Kintara Therapeutics include Genprex (GNPX), Savara (SVRA), scPharmaceuticals (SCPH), Calithera Biosciences (CALA), Jaguar Health (JAGX), Assembly Biosciences (ASMB), Biofrontera (BFRA), Matinas BioPharma (MTNB), Cogent Biosciences (COGT), IMV (IMV), NuCana (NCNA), Heat Biologics (HTBX), Satsuma Pharmaceuticals (STSA), Antibe Therapeutics (ATBPF) and Strongbridge Biopharma (SBBP).
View all of KTRA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), (DMPI), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA."

Kintara Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (2.79%), swisspartners Ltd. (0.85%), Geode Capital Management LLC (0.47%), Citadel Advisors LLC (0.24%), Northern Trust Corp (0.14%) and Envestnet Asset Management Inc. (0.05%).
View institutional ownership trends for Kintara Therapeutics.

KTRA stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, swisspartners Ltd., Geode Capital Management LLC, Citadel Advisors LLC, Northern Trust Corp, and Envestnet Asset Management Inc..
View insider buying and selling activity for Kintara Therapeutics or or view top insider-buying stocks.

Shares of KTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KTRA stock can currently be purchased for approximately $1.32.

Kintara Therapeutics has a market capitalization of $42.74 million. The company earns $-9,130,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

Kintara Therapeutics employs 4 workers across the globe.

The official website for Kintara Therapeutics is www.kintara.com.

Kintara Therapeutics is headquartered at 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130.

Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858 350 4364 or via email at [email protected]